Information Provided By:
Fly News Breaks for June 12, 2018
SYK, BSX
Jun 12, 2018 | 07:00 EDT
Citi analyst Amit Hazan believes Boston Scientific (BSX) could fetch $37-$38 per share in a takeout. The analyst, however, believes an acquisition by Stryker (SYK) "does not have obvious synergies or rationale other than to merge two higher-growing public medtech companies." A deal would, in all likelihood, be accretive, Hazan told investors yesterday in a research note. He assumes a roughly 50/50 debt/equity structure in order to keep Hazan's leverage below 6.0 times. The analyst has a Buy rating on Boston Scientific, saying he really likes the company's prospects for the next couple of years.
News For BSX;SYK From the Last 2 Days
BSX
Mar 26, 2024 | 05:33 EDT
Scivita Medical and Boston Scientific joined hands again to sign an expanded strategic cooperation arrangement. The introduction of iterative endoscopic technology has brought about a positive transformation in the field of endoscopy, making it an interventional tool that combines diagnosis and treatment. Under the arrangement, Scivita Medical will expand its relationship with Boston Scientific for strategic co-development and global distribution activities. Such activities may include collaboration on the co-development of future endoscopic devices, and global distribution opportunities for Scivita Medical's single-use endoscope and imaging devices. It is expected that this expanded arrangement will help bring Scivita Medical products to more hospitals and patients throughout China and other global geographies.